drugset / Trial / NCT06475404
A Study of the Tolerance, Safety, and Pharmacokinetics of GNR-055 in Healthy Volunteers
Non-randomizedSequentialOpen-labelOther
Summary
It is a phase I open-label single-dose, dose-escalation cohort study to evaluate of the tolerance, safety, and pharmacokinetics of GNR-055 in healthy volunteers
Timeline
- Start
- 2023-04-06
- Primary completion
- 2023-09-20
- Completion
- 2023-09-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | verenafusp alfa | Protein / enzyme biologic | 6 mg/kg | Intravenous |
| Subject | verenafusp alfa | Protein / enzyme biologic | 9 mg/kg | Intravenous |
| Subject | verenafusp alfa | Protein / enzyme biologic | 12 mg/kg | Intravenous |